Naeem Lughmani, MD
Sleep Medicine · Sylvania, OHNPI 1013915263
Payments from drug & device makers
Across 942 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Jazz Pharmaceuticals Inc.$3K
- Harmony Biosciences LLC$2K
- GSK$2K
- Boehringer Ingelheim$1K
- Axsome Therapeutics, Inc.$956
- plus $5K from 27 others
What the payments were for
- Food & beverage$15,71395%
- Education$9125%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 136 | $2,711 |
| Jazz Pharmaceuticals Inc. | 148 | $2,618 |
| Harmony Biosciences LLC | 104 | $2,381 |
| GSK | 144 | $2,133 |
| Boehringer Ingelheim | 68 | $1,165 |
| Axsome Therapeutics, Inc. | 89 | $956 |
| Avadel CNS Pharmaceuticals, LLC | 40 | $767 |
| Mylan Specialty L.p. | 51 | $673 |
| Sanofi | 29 | $461 |
| Amgen | 20 | $387 |
| Insmed, Inc. | 14 | $336 |
| Grifols USA, LLC | 15 | $298 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $251 |
| Regeneron Healthcare Solutions, Inc. | 10 | $248 |
| Eisai Inc. | 12 | $244 |
| Merck | 10 | $165 |
| Sanofi-aventis U.S. LLC | 2 | $154 |
| Pfizer | 1 | $124 |
| Sunovion Pharmaceuticals Inc. | 7 | $95 |
| Viatris Specialty LLC | 4 | $87 |
| Circassia Inc. | 4 | $58 |
| Teva Pharmaceuticals USA, Inc. | 3 | $46 |
| Verona Pharma, Inc. | 2 | $43 |
| Idorsia Pharmaceuticals US Inc | 3 | $41 |
| Inspire Medical Systems, Inc. | 2 | $34 |
| Pulmonx Corporation | 2 | $30 |
| Resmed Corp | 2 | $27 |
| 3b Medical, Inc. | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $16 |
| Philips North America LLC | 1 | $16 |
| Fisher & Paykel Healthcare Inc | 1 | $16 |
| Baxter Healthcare | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,624 in reported general payments places this provider in the 85th percentile of 94 sleep medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 552 | $453,040 |
| XywavSodium,calcium,mag,pot Oxybate | 25 | $411,918 |
| Breo ElliptaFluticasone/Vilanterol | 207 | $103,452 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 124 | $99,081 |
| Spiriva RespimatTiotropium Bromide | 94 | $60,691 |
| NucalaMepolizumab | 16 | $59,021 |
| TezspireTezepelumab-Ekko | 12 | $53,834 |
| SunosiSolriamfetol Hcl | 55 | $51,510 |
| Dupixent PenDupilumab | 11 | $41,074 |
| Advair HfaFluticasone Propion/Salmeterol | 78 | $25,659 |
| Incruse ElliptaUmeclidinium Bromide | 35 | $16,257 |
| SymbicortBudesonide/Formoterol Fumarate | 48 | $13,709 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 545 | $13,603 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $13,351 |
| Arnuity ElliptaFluticasone Furoate | 43 | $11,014 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Incruse Ellipta, Anoro Ellipta | $2,133 | $656,135880 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $2,711 | $166,624184 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $1,165 | $67,835109 claims |
| Axsome Therapeutics, Inc.Sunosi | $956 | $51,51055 claims |
| MerckDulera | $165 | $10,46532 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $46 | $3,66616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 94 sleep medicine providers in Ohio.
Other sleep medicine in Sylvania
- Abbey DunnSylvania$4K
- Mohan DuttSylvania$2K
- Serene OzeirSylvania$2K
- Asim RoyDublin$2.2M
- Nancy Foldvary-SchaeferCleveland$1.6M
- Shahrokh JavaheriCincinnati$404K
- Louis TartagliaMaumee$314K
- John AndrefskyParma$147K
- Ulysses MagalangColumbus$143K
- Sally IbrahimCleveland$130K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.